JPH0228596B2 - - Google Patents
Info
- Publication number
- JPH0228596B2 JPH0228596B2 JP56031001A JP3100181A JPH0228596B2 JP H0228596 B2 JPH0228596 B2 JP H0228596B2 JP 56031001 A JP56031001 A JP 56031001A JP 3100181 A JP3100181 A JP 3100181A JP H0228596 B2 JPH0228596 B2 JP H0228596B2
- Authority
- JP
- Japan
- Prior art keywords
- sangenone
- methanol
- benzene
- acetone
- blood pressure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000001875 compounds Chemical class 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 31
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 13
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 240000000249 Morus alba Species 0.000 description 9
- 235000008708 Morus alba Nutrition 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 238000000862 absorption spectrum Methods 0.000 description 6
- 230000004531 blood pressure lowering effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- -1 8-substituted cyclohexenylflavone Chemical class 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- TXHIDIHEXDFONW-UHFFFAOYSA-N benzene;propan-2-one Chemical compound CC(C)=O.C1=CC=CC=C1 TXHIDIHEXDFONW-UHFFFAOYSA-N 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000012746 preparative thin layer chromatography Methods 0.000 description 3
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 2
- FOGVNFMUZXDMTR-UHFFFAOYSA-N [Mg].Cl Chemical compound [Mg].Cl FOGVNFMUZXDMTR-UHFFFAOYSA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000005238 degreasing Methods 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 238000011403 purification operation Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 241000218213 Morus <angiosperm> Species 0.000 description 1
- 235000004839 Morus alba var multicaulis Nutrition 0.000 description 1
- 240000006920 Morus alba var. multicaulis Species 0.000 description 1
- 241000301120 Morus lhou Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- CZCSLHYZEQSUNV-UHFFFAOYSA-N [Na].OB(O)O Chemical compound [Na].OB(O)O CZCSLHYZEQSUNV-UHFFFAOYSA-N 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- RTEXIPZMMDUXMR-UHFFFAOYSA-N benzene;ethyl acetate Chemical compound CCOC(C)=O.C1=CC=CC=C1 RTEXIPZMMDUXMR-UHFFFAOYSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical compound CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000001459 whitebark Nutrition 0.000 description 1
Landscapes
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Compounds Of Unknown Constitution (AREA)
Description
【発明の詳細な説明】
本発明は血圧下降作用を有し、医薬として有用
な新規化合物(サンゲノンC)に関する。さらに
詳しくは、本発明は下記式
で表わされるサンゲノンCに関する。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a novel compound (Sangenone C) that has a blood pressure lowering effect and is useful as a pharmaceutical. More specifically, the present invention is based on the following formula It relates to Sunguenon C represented by
これまで、桑根皮については漢方において桑白
皮と称し、消炎性利尿、緩下、鎮咳去痰剤として
漢方製剤に配合されている。 Until now, mulberry root bark has been referred to as mulberry white bark in Chinese medicine, and has been included in Chinese medicine preparations as an anti-inflammatory diuretic, laxative, and antitussive expectorant.
また最近では、そのメタノールエキスの血圧下
降作用(日本薬学会第99年会講演要旨集、162頁、
29A2−3)、エキス抽出物の過血糖降下作用(特
公昭53−44530号公報)、エキス中に含有している
高分子多糖体のインターフエロン誘起作用(特開
昭53−99313号公報)等が知られている。 In addition, recently, the blood pressure lowering effect of the methanol extract (Proceedings of the 99th Annual Meeting of the Pharmaceutical Society of Japan, p. 162,
29A2-3), hyperglycemic lowering effect of the extract (Japanese Patent Publication No. 53-44530), interferon-inducing effect of the high molecular polysaccharide contained in the extract (Japanese Patent Application Laid-open No. 53-99313), etc. It has been known.
しかしながら、血圧下降作用における活性本体
については、発明者等が発見した本邦産桑根皮中
の2種の8−置換シクロヘキセニルフラボン誘導
体クワノンG及びクワノンH〔ケミカル アンド
フアーマシユーテイカル ブレテイン(Chem.
Pharm.Bull.)28巻、8号、2548頁(1980年)、
ヘテロサイクルズ(HETEROCYCLES)14巻、
12号、1943頁(1980年)〕以外未だ解明されてい
ない。 However, regarding the active substance in the blood pressure lowering effect, two types of 8-substituted cyclohexenylflavone derivatives Quanon G and Quanon H [Chemical and Pharmaceutical Bulletin (Chem.
Pharm.Bull.) Volume 28, No. 8, Page 2548 (1980),
HETEROCYCLES Volume 14,
No. 12, p. 1943 (1980)] have not yet been elucidated.
本発明者は、鋭意研究の結果、クワ科クワ属
(Morus)植物を有機溶媒で抽出し、この抽出エ
キスより単離して得られた新規化合物に血圧下降
作用があることを見出して本発明を完成し、これ
をサンゲノンCと命名した。 As a result of intensive research, the present inventor extracted a plant of the genus Morus, family Moraceae, with an organic solvent, and discovered that a new compound obtained by isolation from this extracted extract has a blood pressure lowering effect, and has developed the present invention. It was completed and named Sangenon C.
まず、サンゲノンCの製造法について説明す
る。 First, a method for producing Sangenone C will be explained.
桑根皮を細切し、比較的極性の小さい有機溶媒
で脱脂処理を行つた後、低級アルコール、低級脂
肪酸エステル、エーテル又はアセトンで抽出過
し、液を減圧乾燥して抽出エキスを得、この抽
出エキスを常法に従いカラムクロマトグラフイー
に付し不純物を分離し、粗サンゲノンCを得る。
次いで、この粗製物を分取薄層クロマトグラフイ
ー或は高速液体クロマトグラフイーに付し、単離
精製してサンゲノンCを製造する。 The mulberry root bark is cut into small pieces, degreased with an organic solvent with relatively low polarity, extracted with lower alcohol, lower fatty acid ester, ether or acetone, and the liquid is dried under reduced pressure to obtain an extracted extract. The extracted extract is subjected to column chromatography according to a conventional method to separate impurities to obtain crude Sangenone C.
Next, this crude product is subjected to preparative thin layer chromatography or high performance liquid chromatography to isolate and purify it to produce Sangenone C.
ここで、原料である桑は中国産の市販桑白皮或
はマグワ(Morus alba L.)、ヤマグワ(Morus
bombycis Koidz)、ロソウ(Morus Lhou
Koidz又はMorus multicaulis Perr.)等が用い
られ、特にその根皮が好ましい。これらは充分乾
燥した細末とする。 The mulberry used here is commercially available mulberry bark from China, Morus alba L., Morus alba L.
bombycis Koidz), Morus Lhou
Koidz or Morus multicaulis Perr.), etc. are used, and the root bark thereof is particularly preferred. These should be thoroughly dried into fine powders.
脱脂処理に使用する比較的極性の小さい有機溶
媒としてはn−ヘキサン、ベンゼン等が適する。 Suitable organic solvents with relatively low polarity for use in the degreasing treatment include n-hexane and benzene.
抽出用の低級アルコールとしてはメタノール、
エタノール等が、低級脂肪酸エステルとしては酢
酸メチル、酢酸エチル、酢酸ブチル等が、エーテ
ルとしてはメチルエーテル、エチルエーテル等が
使用可能である。 Lower alcohols for extraction include methanol,
Examples of the lower fatty acid ester include methyl acetate, ethyl acetate, butyl acetate, and the like, and examples of the ether include methyl ether and ethyl ether.
常法によるカラムクロマトグラフイーとして
は、例えば、シリカゲルを充填したカラムを用い
て、アセトン−ベンゼン混液、メタノール−ベン
ゼン混液、酢酸エチル−ベンゼン混液、又はアセ
トン−n−ヘキサン混液で溶出することにより粗
サンゲノンCを得ることができる。 In conventional column chromatography, for example, a column packed with silica gel is used to elute with an acetone-benzene mixture, methanol-benzene mixture, ethyl acetate-benzene mixture, or acetone-n-hexane mixture. Sangenone C can be obtained.
次いで行なう精製操作については、例えば、シ
リカゲル分取薄層クロマトグラフイーでヘキサ
ン、ベンゼン、クロロホルム、アセトン、酢酸エ
チル又はメタノール等の溶媒を単独で又は混合し
て用いて展開し分取することにより、サンゲノン
Cを得ることができる。 For the subsequent purification operation, for example, by developing and fractionating using silica gel preparative thin layer chromatography using solvents such as hexane, benzene, chloroform, acetone, ethyl acetate, or methanol alone or in combination, Sangenone C can be obtained.
なお、上記抽出・分離操作中、脱脂処理を省略
することも可能である。 Note that it is also possible to omit the degreasing treatment during the above extraction/separation operation.
上記の如く処理して得られるサンゲノンCの物
理的及び化学的性質は次のとおりである。 The physical and chemical properties of Sangenone C obtained by the above treatment are as follows.
(a) 性 状:淡黄色粉末
(b) 分子量:708(フイールド デソープシヨン
マススペクトルのM+より)
(c) 融 点:230〜240℃(分解)
(d) 比旋光度:〔α〕16 D+304゜(C=0.179、メタノ
ール)
(e) 赤外吸収スペクトル(nujol)(cm-1)(第1
図参照)
νnax:3300、1660(肩)、1645、1640、1630、
1600(肩)
(f) 紫外吸収スペクトル(nm)(第2図参照)
λCH3OH nax(logε):220(4.64)、230(4.55)
、283
(4.40)、309(4.35)
λCH3OH+AlCl3 nax(logε):225(4.63)、292(4
.35)、
305(4.40)、350(4.01)、420(3.18)
(g) 核磁気共鳴スペクトル(CD3COCD3)
(ppm)
δ:1.53、1.61、1.88(各々3H、s)、2.20〜
2.50(2H、m)、2.50〜3.30(2H、m)、
3.80〜4.00(1H、m)、4.00〜4.30(1H、
m)、4.57(1H、t、J=6Hz)、5.22
(1H、brt、J=7Hz)、5.58(1H、brs)、
5.77(1H、s)、6.15〜6.60(6H、m)、
6.97(1H、d、J=8Hz)、7.33(1H、
d、J=8Hz)、8.41(1H、d、J=8
Hz)、12.15(1H、s)、12.48(1H、s)
(h) 呈色反応
塩化第二鉄反応 陽性(赤紫色)
塩酸−マグネシウム反応 陽性(橙色)
水酸化ホウ素ナトリウム反応 陽性(紫色)
(i) 分子式:C40H36O12
(j) 溶媒に対する溶解性
難溶:水、ヘキサン、ベンゼン、クロロホル
ム、ジクロロメタン
可溶:エチルエーテル、酢酸エチル
易溶:メタノール、エタノール、ジメチルホ
ルムアミド、アセトン
(k) 酸性、中性、塩基性の区別:酸性
上記サンゲノンCの血圧下降作用は以下に示す
動物実験により確認した。(a) Properties: Pale yellow powder (b) Molecular weight: 708 (field desorption)
(from mass spectrum M + ) (c) Melting point: 230-240℃ (decomposition) (d) Specific rotation: [α] 16 D +304° (C = 0.179, methanol) (e) Infrared absorption spectrum (nujol ) (cm -1 ) (1st
(See figure) ν nax : 3300, 1660 (shoulder), 1645, 1640, 1630,
1600 (shoulder) (f) Ultraviolet absorption spectrum (nm) (see Figure 2) λ CH3OH nax (logε): 220 (4.64), 230 (4.55)
, 283
(4.40), 309 (4.35) λ CH3OH+AlCl3 nax (logε): 225 (4.63), 292 (4
.35),
305 (4.40), 350 (4.01), 420 (3.18) (g) Nuclear magnetic resonance spectrum (CD 3 COCD 3 )
(ppm) δ: 1.53, 1.61, 1.88 (3H, s respectively), 2.20~
2.50 (2H, m), 2.50~3.30 (2H, m),
3.80~4.00 (1H, m), 4.00~4.30 (1H,
m), 4.57 (1H, t, J=6Hz), 5.22
(1H, brt, J=7Hz), 5.58 (1H, brs),
5.77 (1H, s), 6.15-6.60 (6H, m),
6.97 (1H, d, J=8Hz), 7.33 (1H,
d, J=8Hz), 8.41(1H, d, J=8
Hz), 12.15 (1H, s), 12.48 (1H, s) (h) Color reaction Ferric chloride reaction Positive (reddish purple) Hydrochloric acid-magnesium reaction Positive (orange) Sodium boron hydroxide reaction Positive (purple) ( i) Molecular formula: C 40 H 36 O 12 (j) Solubility in solvents Poorly soluble: water, hexane, benzene, chloroform, dichloromethane Soluble: ethyl ether, ethyl acetate Easily soluble: methanol, ethanol, dimethylformamide, acetone (k) ) Distinction between acidic, neutral, and basic: Acidic The blood pressure lowering effect of Sangenone C was confirmed by the following animal experiment.
まず試料をプロピレングリコールに10mg/mlの
濃度になるよう溶解、調製し、麻酔下(ペントバ
ルビタール30mg/Kg、静注)の体重3.0Kgの雄性
家兎に静注して、大腿動脈血圧を測定した。 First, the sample was dissolved and prepared in propylene glycol to a concentration of 10 mg/ml, and the sample was injected intravenously into a male rabbit weighing 3.0 kg under anesthesia (pentobarbital 30 mg/Kg, intravenous injection) to measure femoral artery blood pressure. did.
その結果、1mg/Kgの投与量で一過性に15mm
Hg、5mg/Kgの投与量で一過性に100mmHg引き
続いて1時間以上15mmHgの血圧下降が見られた。 As a result, a dose of 1 mg/Kg transiently caused 15 mm
At a dose of 5 mg/Kg of Hg, a transient drop in blood pressure of 100 mmHg followed by 15 mmHg for over 1 hour was observed.
又、急性毒性におけるLD50はマウス(5週齢、
ddY系、雄性)腹腔内投与で132mg/Kgであつた。 In addition, the LD 50 for acute toxicity is for mice (5 weeks old,
ddY strain, male) was 132 mg/Kg when administered intraperitoneally.
以上述べたように、前記の物理的及び化学的性
質を有するサンゲノンCは、桑根皮より比較的簡
単な抽出精製操作により製造することができ、
又、優れた血圧下降作用を示し、しかも毒性が低
いので降圧剤として好適である。 As mentioned above, Sangenone C having the above-mentioned physical and chemical properties can be produced from mulberry root bark through a relatively simple extraction and purification operation.
In addition, it exhibits an excellent blood pressure lowering effect and has low toxicity, making it suitable as an antihypertensive agent.
以下に本発明のサンゲノン化合物(サンゲノン
C)の製造法を具体的に説明する。 The method for producing the Sangenone compound (Sangenone C) of the present invention will be specifically explained below.
製造例
細切した乾燥市販桑白皮(中国広東省産)8Kg
をn−ヘキサン40で2回、更にベンゼン40で
2回、いずれも室温で1週間脱脂処理し、次いで
メタノール40で2回、室温で各3日間抽出を行
ない、抽出液を取し、減圧下溶媒を留去した
後、酢酸エチル1を加え、可溶部を分取した。
この、酢酸エチル可溶部より減圧下溶媒を留去
し、抽出エキス70gを得た。Production example: Shredded dried commercially available mulberry bark (produced in Guangdong, China) 8Kg
was degreased twice with n-hexane 40 and then twice with benzene 40 at room temperature for one week, then extracted twice with methanol 40 at room temperature for 3 days each, and the extract was collected and extracted under reduced pressure. After distilling off the solvent, 1 portion of ethyl acetate was added, and the soluble portion was separated.
The solvent was distilled off under reduced pressure from the ethyl acetate soluble portion to obtain 70 g of extracted extract.
この抽出エキス36gを必要最少量のアセトンに
溶解し、シリカゲル(ワコーゲルC−200、和光
純薬工業製)70gに吸着させ、溶媒を蒸発除去し
た後、シリカゲル300gを充填したカラムの上に
層積充填し、まず15%アセトン−ベンゼンを展開
溶媒として10溶出を行つた後、20%アセトン−
ベンゼン5にて溶出し、この溶出液を減圧濃縮
して粗サンゲノンC13.0gを得た。 36g of this extracted extract was dissolved in the minimum amount of acetone required, adsorbed on 70g of silica gel (Wako Gel C-200, manufactured by Wako Pure Chemical Industries, Ltd.), the solvent was removed by evaporation, and a layer was placed on a column packed with 300g of silica gel. First, elute 10 times using 15% acetone-benzene as a developing solvent, then elute with 20% acetone-benzene.
Elution was performed with 5 portions of benzene, and the eluate was concentrated under reduced pressure to obtain 13.0 g of crude Sangenone C.
この粗サンゲノンCを分取薄層クロマトグラフ
イー〔ワコーゲルB−5F(和光純薬工業製)、展
開溶媒;メタノール:クロロホルム=1:5〕で
精製し、サンゲノンC3.0gを得た。その物理的及
び化学的性質は下記の通りであつた。 This crude Sangenone C was purified by preparative thin layer chromatography [Wako Gel B-5F (manufactured by Wako Pure Chemical Industries, Ltd.), developing solvent: methanol:chloroform = 1:5] to obtain 3.0 g of Sangenone C. Its physical and chemical properties were as follows.
(a) 性 状:淡黄色粉末
(b) 分子量:708(フイールド デソープシヨン
マススペクトルのM+より)
(c) 融 点:230〜240℃(分解)
(d) 比旋光度:〔α〕16 D+304゜(C=0.179、メタノ
ール)
(e) 赤外吸収スペクトル(nujol)(cm-1)
νnax:3300、1660(肩)、1645、1640、1630、
1600(肩)
(f) 紫外吸収スペクトル(nm)
λCH3OH nax(logε):220(4.64)、230(4.55)
、283
(4.40)、309(4.35)
λCH3OH+AlCl3 nax(logε):225(4.63)、292(4
.35)、
305(4.40)、350(4.01)、420(3.18)
(g) 呈色反応
塩化第二鉄反応 陽性(赤紫色)
塩酸−マグネシウム反応 陽性(橙色)
水素化ホウ素ナトリウム反応 陽性(紫色)
(h) 溶媒に対する溶解性
難溶:水、ヘキサン、ベンゼン、クロロホル
ム、ジクロロメタン
可溶:エチルエーテル、酢酸エチル
易溶:メタノール、エタノール、ジメチルホ
ルムアミド、アセトン
(i) 酸性、中性、塩基性の区別:酸性
(j) 元素分析値
実験値(%);C:65.61、H:5.31(a) Properties: Pale yellow powder (b) Molecular weight: 708 (field desorption)
(from mass spectrum M + ) (c) Melting point: 230-240℃ (decomposition) (d) Specific rotation: [α] 16 D +304° (C = 0.179, methanol) (e) Infrared absorption spectrum (nujol ) (cm -1 ) ν nax : 3300, 1660 (shoulder), 1645, 1640, 1630,
1600 (shoulder) (f) Ultraviolet absorption spectrum (nm) λ CH3OH nax (logε): 220 (4.64), 230 (4.55)
, 283
(4.40), 309 (4.35) λ CH3OH+AlCl3 nax (logε): 225 (4.63), 292 (4
.35),
305 (4.40), 350 (4.01), 420 (3.18) (g) Color reaction Ferric chloride reaction Positive (reddish purple) Hydrochloric acid-magnesium reaction Positive (orange) Sodium borohydride reaction Positive (purple) (h) Solubility in solvents Poorly soluble: water, hexane, benzene, chloroform, dichloromethane Soluble: ethyl ether, ethyl acetate Easily soluble: methanol, ethanol, dimethylformamide, acetone (i) Distinction between acidic, neutral, and basic: acidic ( j) Elemental analysis value Experimental value (%); C: 65.61, H: 5.31
第1図は本発明のサンゲノン化合物の赤外吸収
スペクトル(nujol)を示す図、第2図は本発明
のサンゲノン化合物の紫外吸収スペクトル(メタ
ノール中)を示す図である。
FIG. 1 is a diagram showing the infrared absorption spectrum (nujol) of the sungenone compound of the present invention, and FIG. 2 is a diagram showing the ultraviolet absorption spectrum (in methanol) of the sungenone compound of the present invention.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP56031001A JPS57145894A (en) | 1981-03-04 | 1981-03-04 | Sanggenon compound |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP56031001A JPS57145894A (en) | 1981-03-04 | 1981-03-04 | Sanggenon compound |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS57145894A JPS57145894A (en) | 1982-09-09 |
JPH0228596B2 true JPH0228596B2 (en) | 1990-06-25 |
Family
ID=12319330
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP56031001A Granted JPS57145894A (en) | 1981-03-04 | 1981-03-04 | Sanggenon compound |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS57145894A (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108261346B (en) * | 2018-03-01 | 2020-12-29 | 上海科颜生物科技有限公司 | Whitening composition and preparation method thereof |
-
1981
- 1981-03-04 JP JP56031001A patent/JPS57145894A/en active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS57145894A (en) | 1982-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100595183C (en) | Method for preparing 6-gingerol and 8-gingerol from ginger | |
Fried et al. | The hypotensive principles of Veratrum viride | |
JP2732259B2 (en) | New aconitine compounds and analgesic / anti-inflammatory agents | |
JP2005179339A (en) | New compound and medicinal composition | |
JPH0228596B2 (en) | ||
JPH0228597B2 (en) | ||
JPH0260680B2 (en) | ||
JPH0149152B2 (en) | ||
JPH0114232B2 (en) | ||
JPH021824B2 (en) | ||
JPS6011017B2 (en) | Production method of diterpene alcohol | |
JPH0952899A (en) | Leucotriene antagonist | |
Penttilä et al. | Isolation, structure, and synthesis of margaspidin, a new dryopteris phloroglucinol derivative | |
JPH0226614B2 (en) | ||
JPS6112660A (en) | Novel 2-pyrrolidone derivative and antiinflammatory therefrom | |
JPS6048493B2 (en) | New compound, its production method, and antipyretic agent containing it as an active ingredient | |
JPH0631245B2 (en) | Novel quassinoid compound and method for producing the same | |
JPS6051476B2 (en) | New diterpene derivatives | |
JPS602294B2 (en) | Novel compound, its production method, and antipyretic agent containing it as an active ingredient | |
JPS6411005B2 (en) | ||
JPH01207298A (en) | Prost-13(17)ene-3,16-dione compound | |
JPS625885B2 (en) | ||
CN111217719A (en) | Alkaloid, and extraction method and application from black pepper | |
JPH01290678A (en) | Benzylisoquinoline compound | |
JPH03294273A (en) | Tristilbene compound |